María Río, vice president and general director of Gilead Sciences Spain and Portugal, and Marina Pollán, director of the Carlos III Health Institute (ISCIII), an organization dependent on the Ministry of Science, Innovation and Universities, have signed the collaboration agreement of the XI edition of the Gilead Scholarships for Biomedical Research.
These scholarships, which are aimed at promoting R&D in our country and recognizing the work of Spanish researchers, They have been held for more than a decade, with an approximate investment of one million euros. Aid that is possible thanks to the collaboration between Gilead and the ISCIII, an entity that guarantees that the review process of research projects meets the principles of transparency, objectivity and independence necessary for the correct choice of projects to finance.
“It is with great satisfaction that I announce that the 11th edition of the Gilead Scholarships for Biomedical Innovation is now underway. This initiative It is one of the most important among those organized in our country in the field of research., and it is a pride to see how it is consolidated and how it continues to celebrate years of supporting Spanish researchers. As always, the experience and good work of the Carlos III Health Institute are a guarantee of the rigor and scientific quality of the projects that will be selected,” said María Rio, vice president and general director of Gilead Spain and Portugal.
According to Marina Pollán, director of the ISCIII, “at the Institute we find it very important to continue supporting this type of public-private collaboration initiatives, which allow us to consolidate different avenues to promote health research. As in previous years, our participation in the evaluation of projects of these scholarships represents a new example of the ISCIII’s commitment to the generation of scientific knowledge to care for people’s health“.
Excellence in research
Over the years, Gilead has covered different therapeutic areas to promote research in those areas and pathologies that have urgent unmet medical needs. In this way, in this edition we will recognize the best research works in HIV, Covid-19, Hepatitis Delta, B-cell non-Hodgkin lymphomas and Medical Oncology, for which there will be the collaboration of the main scientific societies and collaborative groups of these disciplines.
The evaluation of the projects will be carried out by the ISCIII, an entity that has its own experience and quality standards and the participation of national and international peer evaluators for each project.
Furthermore, in this eleventh edition – for the fourth consecutive year – special recognition to those works presented by young researchers. An initiative with which Gilead and the ISCIII seek to highlight research work and promote the experience and talent of younger Spanish scientists in different areas with medical needs yet to be covered.
